Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarve, Indrajeet J.en_US
dc.contributor.authorChen, Li-Hsunen_US
dc.contributor.authorWei, Patrick C. P.en_US
dc.contributor.authorHung, Jui-Teen_US
dc.contributor.authorSun, Chung-Mingen_US
dc.date.accessioned2014-12-08T15:29:45Z-
dc.date.available2014-12-08T15:29:45Z-
dc.date.issued2013-04-01en_US
dc.identifier.issn0040-4020en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.tet.2013.01.061en_US
dc.identifier.urihttp://hdl.handle.net/11536/21370-
dc.description.abstractEnantioselective synthesis of clinically approved drug Silodosin for the treatment of benign prostatic hyperplasia from the commercially available compounds 1-acetyl-5-(2-aminopropyl) indoline-7-carbonitrile A and 2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl methanesulfonate C is explored. Key step in the synthesis is chiral resolution of intermediate I, which was achieved by a simple diastereomeric crystallization using (S)-(+)-mandelic acid assisted by ultrasonication. The present synthetic strategy has lesser number of steps and is vastly improved the overall yield in this short route towards target compound Silodosin. (C) 2013 Elsevier Ltd. All rights reserved.en_US
dc.language.isoen_USen_US
dc.titleEnantioselective synthesis of (-)-(R) Silodosin by ultrasound-assisted diastereomeric crystallizationen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.tet.2013.01.061en_US
dc.identifier.journalTETRAHEDRONen_US
dc.citation.volume69en_US
dc.citation.issue13en_US
dc.citation.spage2834en_US
dc.citation.epage2843en_US
dc.contributor.department應用化學系zh_TW
dc.contributor.departmentDepartment of Applied Chemistryen_US
dc.identifier.wosnumberWOS:000315843800020-
dc.citation.woscount1-
Appears in Collections:Articles


Files in This Item:

  1. 000315843800020.pdf

If it is a zip file, please download the file and unzip it, then open index.html in a browser to view the full text content.